[0311] In some embodiments, the compositions of the disclosure contain at least about 0.01 %, at least about 0.05 %, at least about 0.1 %, at least about 0.2 %, at least about 0.3 %, at least about 0.4 %, at least about 0.5 %, at least about 0.6 %, at least about 0.7 %, at least about 0.8 %, at least about 0.9 %, at least about 1.0 %, at least about 1.5 %, at least about 2.0 %, at least about 2.5 %, at least about 3.0 %, at least about 3.5 %, at least about 4.0 %, at least about 4.5 %, at least about 5.0 %, at least about 5.5 %, at least about 6.0 %, at least about 6.5 %, at least about 7.0 %, at least about 7.5 %, at least about 8.0 %, at least about 8.5 %, at least about 9.0 %, at least about 9.5 %, at least about 10 %, at least about 11 %, at least about 12 %, at least about 13 %, at least about 14 %, at least about 15 %, at least about 16 %, at least about 17 %, at least about 18 %, at least about 19 %, at least about 20 %, at least about 21 %, at least about 22 %, at least about 23 %, at least about 24 %, at least about 25 %, at least about 26 %, at least about 27 %, at least about 28 %, at least about 29 %, at least about 30 %, at least about 31 %, at least about 32 %, at least about 33 %, at least about 34 %, at least about 35 %, at least about 36 %, at least about 37 %, at least about 38 %, at least about 39 %, at least about 40 %, at least about 41 %, at least about 42 %, at least about 43 %, at least about 44 %, at least about 45 %, at least about 46 %, at least about 47 %, at least about 48 %, at least about 49 %, at least about 50 %, at least about 51 %, at least about 52 %, at least about 53 %, at least about 54 %, at least about 55%, at least about 56 %, at least about 57 %, at least about 58 %, at least about 59 %, at least about 60 %, at least about 61 %, at least about 62 %, at least about 63 %, at least about 64 %, at least about 65 %, at least about 66 %, at least about 67 %, at least about 68 %, at least about 69 %, at least about 70 %, at least about 71 %, at least about 72 %, at least about 73 %, at least about 74 %, at least about 75 %, at least about 76 %, at least about 77 %, at least about 78 %, at least about 79 %, at least about 80 %, at least about 81 %, at least about 82 %, at least about 83 %, at least about 84 %, at least about 85 %, at least about 86 %, at least about 87 %, at least about 88 %, at least about 89 %, at least about 90 %, at least about 91 %, at least about 92 %, at least about 93 %, at least about 94 %, at least about 95 %, at least about 96 %, at least about 97 %, at least about 98 %, or at least about 99 % mitophagy stimulant (e.g., urolithin A) by weight of the composition
NICE accepted our call for a Guideline in late 2018, but it has sat in the in-tray of the organisation since then
Let your skin breathe and give it time to heal properly
It is not a direct menstrual treatment, but can assist recovery from pelvic tissue injury or inflammation that secondarily impacts cycles
Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray
